Issue 4, 2020

A nanoscale, biocompatible and amphiphilic prodrug of cabazitaxel with improved anticancer efficacy against 3D spheroids of prostate cancer cells

Abstract

Chemotherapy is still a major therapeutic approach for the treatment of cancer. Cabazitaxel (CTX) is a highly effective anticancer drug for the treatment of prostate cancer. However, insolubility in water and non-specific drug delivery are major challenges in its application. In this study, we have designed pH-responsive and water-soluble prodrugs of CTX using pluronic F68 and pH-sensitive linkers for its site-specific delivery. The synthesized pluronic F68–CTX conjugates (F68–SA–CTX via a succinoyl linker; and F68–CAA–CTX via a cis-aconityl linker) were characterized through 1H-NMR and FTIR analysis. The nanomicelles of the amphiphilic prodrugs of CTX were self-assembled in water and demonstrated a low critical micelle concentration, a particle size of about 95 nm, monodispersity, spherical shape, and pH-responsive stability. Comparatively, cis-aconityl linker-based nanomicelles exhibited better pH-responsiveness and control over the release of CTX in comparison to succinoyl linker-based nanomicelles. Furthermore, the cis-aconityl linked nanomicelles showed greater inhibition of growth of human prostate cancer cells, stimulated higher ROS generation, decreased mitochondrial membrane potential and induced greater apoptosis without changing the cell cycle arrest mechanism of CTX. Thus, the present prodrug formulation of CTX is more advantageous than its conventional formulation.

Graphical abstract: A nanoscale, biocompatible and amphiphilic prodrug of cabazitaxel with improved anticancer efficacy against 3D spheroids of prostate cancer cells

Supplementary files

Article information

Article type
Paper
Submitted
10 Apr 2020
Accepted
01 Jun 2020
First published
01 Jun 2020
This article is Open Access
Creative Commons BY-NC license

Mater. Adv., 2020,1, 738-748

A nanoscale, biocompatible and amphiphilic prodrug of cabazitaxel with improved anticancer efficacy against 3D spheroids of prostate cancer cells

A. K. Jangid, D. Pooja, P. Jain, S. V. K. Rompicharla, S. Ramesan and H. Kulhari, Mater. Adv., 2020, 1, 738 DOI: 10.1039/D0MA00189A

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements